A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Capecitabine (Primary) ; Varlitinib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Registrational; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 08 Jan 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
- 08 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2020.
- 21 Sep 2018 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO)